3/17
03:04 pm
cor
Cencora (COR) was given a new $380.00 price target by Morgan Stanley.
Low
Report
Cencora (COR) was given a new $380.00 price target by Morgan Stanley.
3/17
02:13 pm
cor
Cencora (COR) had its "outperform" rating reaffirmed by Leerink Partners.
Low
Report
Cencora (COR) had its "outperform" rating reaffirmed by Leerink Partners.
3/17
12:05 pm
cor
Cencora (COR) had its "outperform" rating reaffirmed by Evercore Inc.
Low
Report
Cencora (COR) had its "outperform" rating reaffirmed by Evercore Inc.
3/17
08:49 am
cor
Cencora Announces Financial Leadership Transition [Yahoo! Finance]
Low
Report
Cencora Announces Financial Leadership Transition [Yahoo! Finance]
3/17
08:30 am
cor
Cencora Announces Financial Leadership Transition
Low
Report
Cencora Announces Financial Leadership Transition
3/10
05:38 pm
cor
Cencora, Inc. (COR) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
Low
Report
Cencora, Inc. (COR) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
3/10
11:36 am
cor
Cencora, Inc. (COR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Cencora, Inc. (COR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/7
09:23 pm
cor
Assessing Cencora (COR) Valuation As Recent Pullback Meets Strong One Year Shareholder Return [Yahoo! Finance]
Low
Report
Assessing Cencora (COR) Valuation As Recent Pullback Meets Strong One Year Shareholder Return [Yahoo! Finance]
3/6
10:58 am
cor
Is Cencora Stock Outperforming the S&P 500? [Yahoo! Finance]
Low
Report
Is Cencora Stock Outperforming the S&P 500? [Yahoo! Finance]
3/6
07:13 am
cor
Kedrion Activates Nationwide Distribution Network for QIVIGY® in the U.S. [Yahoo! Finance]
Low
Report
Kedrion Activates Nationwide Distribution Network for QIVIGY® in the U.S. [Yahoo! Finance]
2/27
10:53 am
cor
Gallant Announces First-of-Its-Kind Partnership with MWI Animal Health to Deliver Anticipated FDA-Conditionally Approved Stem Cell Therapy into Veterinary Clinics [Yahoo! Finance]
Low
Report
Gallant Announces First-of-Its-Kind Partnership with MWI Animal Health to Deliver Anticipated FDA-Conditionally Approved Stem Cell Therapy into Veterinary Clinics [Yahoo! Finance]
2/23
06:03 am
cor
Healthcare Logistics Industry Report 2026-2035: A $213.74 Billion Market by 2030 with AmerisourceBergen, CEVA Logistics, Cold Chain Technologies, Deutsche Post DHL Group, and UPS Healthcare Leading [Yahoo! Finance]
Low
Report
Healthcare Logistics Industry Report 2026-2035: A $213.74 Billion Market by 2030 with AmerisourceBergen, CEVA Logistics, Cold Chain Technologies, Deutsche Post DHL Group, and UPS Healthcare Leading [Yahoo! Finance]
2/20
05:22 am
cor
Bio-Pharmaceutical Logistics Market Report 2026-2035: A $259.32 Billion Market by 2030 with Kuehne + Nagel, FedEx, AmerisourceBergen, UPS, Kerry Logistics, and DB Schenker Leading [Yahoo! Finance]
Low
Report
Bio-Pharmaceutical Logistics Market Report 2026-2035: A $259.32 Billion Market by 2030 with Kuehne + Nagel, FedEx, AmerisourceBergen, UPS, Kerry Logistics, and DB Schenker Leading [Yahoo! Finance]
2/18
07:31 am
cor
Cencora's animal health unit to merge with Covetrus in $3.5 billion deal [Yahoo! Finance Canada]
Low
Report
Cencora's animal health unit to merge with Covetrus in $3.5 billion deal [Yahoo! Finance Canada]
2/18
07:21 am
cor
Cencora's animal health unit to merge with Covetrus in $3.5 billion deal [Yahoo! Finance]
Low
Report
Cencora's animal health unit to merge with Covetrus in $3.5 billion deal [Yahoo! Finance]
2/18
07:00 am
cor
Covetrus and MWI Animal Health to Merge
Low
Report
Covetrus and MWI Animal Health to Merge
2/13
04:15 pm
cor
Cencora Closes $3.0 Billion Senior Notes Offering
Low
Report
Cencora Closes $3.0 Billion Senior Notes Offering
2/13
07:17 am
cor
Cencora (NYSE:COR) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Low
Report
Cencora (NYSE:COR) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
2/10
05:15 pm
cor
Cencora Prices $500 Million 3.950% Senior Notes Due 2029, $500 Million 4.250% Senior Notes Due 2030, $500 Million 4.600% Senior Notes Due 2033, $1.0 Billion 4.900% Senior Notes Due 2036 and $500 Million 5.650% Senior Notes Due 2056
Low
Report
Cencora Prices $500 Million 3.950% Senior Notes Due 2029, $500 Million 4.250% Senior Notes Due 2030, $500 Million 4.600% Senior Notes Due 2033, $1.0 Billion 4.900% Senior Notes Due 2036 and $500 Million 5.650% Senior Notes Due 2056
2/10
03:28 pm
cor
Cencora (NYSE:COR) had its price target raised by analysts at JPMorgan Chase & Co. from $417.00 to $419.00. They now have an "overweight" rating on the stock.
Low
Report
Cencora (NYSE:COR) had its price target raised by analysts at JPMorgan Chase & Co. from $417.00 to $419.00. They now have an "overweight" rating on the stock.
2/10
07:13 am
cor
Cencora (NYSE:COR) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Low
Report
Cencora (NYSE:COR) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
2/9
10:51 am
cor
Chief Executives for Corporate Purpose Announces Covista Chairman and CEO Steve Beard, Cencora Inc. Former Executive Chair Steven H. Collis, and Ann Fairchild, interim President and CEO of Siemens USA Joining Board of Directors [Yahoo! Finance]
Low
Report
Chief Executives for Corporate Purpose Announces Covista Chairman and CEO Steve Beard, Cencora Inc. Former Executive Chair Steven H. Collis, and Ann Fairchild, interim President and CEO of Siemens USA Joining Board of Directors [Yahoo! Finance]
2/6
06:44 pm
cor
Cencora (NYSE:COR) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b)" rating.
Low
Report
Cencora (NYSE:COR) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b)" rating.
2/5
03:49 pm
cor
Cencora (COR) Stock Trades Up, Here Is Why [Yahoo! Finance]
Low
Report
Cencora (COR) Stock Trades Up, Here Is Why [Yahoo! Finance]
2/5
09:41 am
cor
Cencora (NYSE:COR) had its price target lowered by analysts at Evercore ISI from $440.00 to $420.00. They now have an "outperform" rating on the stock.
Low
Report
Cencora (NYSE:COR) had its price target lowered by analysts at Evercore ISI from $440.00 to $420.00. They now have an "outperform" rating on the stock.